Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Crescent Biopharma ( (CBIO) ) has provided an update.
On July 29, 2025, Crescent Biopharma‘s Board of Directors approved an Executive Severance Plan for its senior employees, providing severance benefits in case of employment termination without cause or resignation for good reason. This plan includes enhanced benefits if termination occurs around a change in control of the company. Additionally, Crescent Biopharma reported significant developments in the second quarter of 2025, including a merger with GlycoMimetics, a $200 million private financing, and leadership appointments. The company is advancing its lead program, CR-001, with plans to submit an IND application by the end of 2025, aiming to initiate a global Phase 1 trial in early 2026.
The most recent analyst rating on (CBIO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Crescent Biopharma stock, see the CBIO Stock Forecast page.
More about Crescent Biopharma
Crescent Biopharma is a biotechnology company focused on developing next-generation therapies for cancer patients. Its primary products include a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, targeting solid tumors.
Average Trading Volume: 72,560
Technical Sentiment Signal: Sell
Current Market Cap: $170.9M
See more insights into CBIO stock on TipRanks’ Stock Analysis page.